Comparative Safety, Efficacy and Survival Outcome of Anti-PD-1 Immunotherapy in Colorectal Cancer Patients With vs Without Hepatitis B Virus Infection: A Multicenter Cohort Study

INTRODUCTION: Antiprogrammed cell death protein-1 (PD-1) immunotherapy has substantially broadened in scope for the treatment of colorectal cancer (CRC). However, comparative safety, efficacy and survival outcome of anti-PD-1 therapy in CRC patients with and without hepatitis B virus (HBV) infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yi-Kan, Chen, Ping, Chen, Dong-Wen, Lin, Zhen-sen, Ye, Shu-Biao, Lan, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132513/
https://www.ncbi.nlm.nih.gov/pubmed/35297794
http://dx.doi.org/10.14309/ctg.0000000000000475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132513/
https://www.ncbi.nlm.nih.gov/pubmed/35297794
http://dx.doi.org/10.14309/ctg.0000000000000475

Ejemplares similares